Impact of the aging tumor microenvironment on immune checkpoint inhibitors therapy

doi:10.16352/j.issn.1001-6325.2025.09.1139

Abstract

Abstract: The role of tumor microenvironment(TME) in tumor genesis and progression has attracted increasing attention. This review describes the effects of aging on the function of immune cells, extra cellular matrix, vasculature, cytokines, and metabolites in the tumor microenvironment, which may alter the host's response to immune checkpoint inhibitors (ICIs) and relies on the results of the most recent clinical studies to evaluate the safety of ICIs for elderly oncology patients and potential adverse effects.

Key words: tumor microenvironment, extracellular matrix, aging, immune checkpoint inhibitors

CLC Number:

ZHOU Huicong, SHAO Yajuan. Impact of the aging tumor microenvironment on immune checkpoint inhibitors therapy[J]. Basic & Clinical Medicine, 2025, 45(9): 1139-1143.

References 30

[1]	郑荣寿, 陈茹,韩冰峰,等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2024,46:221-231.
[2]	Aunan JR, Cho WC, Soreide K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks[J]. Aging Dis, 2017, 8:628-642.
[3]	Fane M, Weeraratna AT. How the ageing microenviron-ment influences tumour progression[J]. Nat Rev Cancer,2020,20:89-106.
[4]	Pilley SE, Esparza E, Mullen PJ. The aging tumor metabolic microenvironment[J]. Curr Opin Biotechnol,2023,84:102995-103002.
[5]	Zhao BH, Wu B, Feng N, et al. Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications[J]. J Hematol Oncol, 2023, 16:27-34.
[6]	Binnewies M, Roberts EW, Kersten K,et al. Understand-ing the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med, 2018, 24:541-550.
[7]	Daste A, Domblides C, Gross-Goupil M, et al. Immune checkpoint inhibitors and elderly people: a review[J]. Eur J Cancer, 2017, 82:155-166.
[8]	Jackaman C, Tomay F, Duong L, et al. Aging and cancer: the role of macrophages and neutrophils[J]. Ageing Res Rev, 2017, 36:105-116.
[9]	Tang T, Huang X, Zhang G, et al. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy[J]. Signal Transduct Target Ther, 2021, 6:72-85.
[10]	Chen S, Saeed AFUH, Liu Q, et al. Macrophages in immunoregulation and therapeutics[J]. Signal Transduct Target Ther, 2023, 8:207-242.
[11]	Kawashima S, Togashi Y. Resistance to immune check-point inhibitors and the tumor microenvironment[J]. Exp Dermatol, 2023, 32:240-249.
[12]	Ohtani N. The roles and mechanisms of senescence-associated secretory phenotype (SASP): Can it be controlled by senolysis?[J]. Inflamm Regen, 2022, 42:11-19.
[13]	Liu JY, Liu JY, Qin GH, et al. MDSCs-derived GPR84 induces CD8+T-Cell senescence via P53 activation to suppress the antitumor response[J]. J Immunother Cancer, 2023, 11:e007802-e007816.
[14]	Sidharth SJ, Giselle BS, Harry S, et al. The role of aging and senescence in immune checkpoint inhibitor response and toxicity[J]. Int J Mol Sci, 2024, 25:7013-7023.
[15]	Hynes RO. The extracellular matrix: not just pretty fibrils[J]. Science, 2009, 326:1216-1219.
[16]	Ontiveros CO, Murray CE, Crossland G, et al. Considerations and approaches for cancer immunotherapy in the aging host[J]. Cancer Immunol Res, 2023, 11:1449-1461.
[17]	Coppé JP, Desprez PY, Krtolica A, et al.The senescence-associated secretory phenotype: the dark side of tumor suppression[J]. Annu Rev Pathol, 2010:5:99-118.
[18]	Lau L, Porciuncula A, Yu A, et al. Uncoupling the senescence-associated secretory phenotype from cell cycle exit via interleukin-1 inactivation unveils its protumori-genic role[J]. Mol Cell Biol, 2019, 39:e00586-e00604.
[19]	Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285:1182-1186.
[20]	Ruscetti M, Morris JP, Mezzadra R, et al. Senescence-induced vascular remodeling creates therapeutic vulner-abilities in pancreas cancer[J]. Cell, 2020, 181:424-441.e21.
[21]	Ramasamy SK, Kusumbe AP, Schiller M, et al. Blood flow controls bone vascular function and osteogenesis[J]. Nat Commun, 2016, 7:13601-136014.
[22]	Gu J, Zhou J, Chen Q, et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells[J]. Cell Rep, 2022, 39:110986-111004.
[23]	Noe JT, Rendon BE, Geller AE, et al. Lactate supports a metabolic-epigenetic link in macrophage polarization[J]. Sci Adv, 2021, 7:8602-8614.
[24]	Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells[J]. Cell Metab, 2016, 24:657-671.
[25]	Kopinski PK, Singh LN, Zhang S, et al. Mitochondrial DNA variation and cancer[J]. Nat Rev Cancer, 2021, 21:431-445.
[26]	Gomes AP, Ilter D, Low V, et al. Age-induced accumulation of methylmalonic acid promotes tumour progression[J]. Nature, 2020, 585:284-287.
[27]	Wong SK, Nebhan CA, Johnson DB. Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy[J].Front Immunol, 2021, 12, 786046-786054.
[28]	Pawelec G. Does patient age influence anti-cancer immunity?[J]. Semin Immunopathol, 2019, 41:125-131.
[29]	Baldini C, Martin Romano P, V oisin AL, et al. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies[J]. Eur J Cancer, 2020, 129:71-79.
[30]	Maria FS, Andrea A, Peio A, et al. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family[J]. J Immunother Cancer, 2023, 11: e007530-e007543.